XKRX
099430
Market cap149mUSD
Jul 10, Last price
4,000.00KRW
1D
2.96%
1Q
-23.95%
IPO
-49.61%
Name
BioPlus Co Ltd
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Seongnam-si, South Korea, Bio Plus Co., Ltd, established in 2003, is dedicated to the investigation, formulation, production, and commercialization of bio-based items. The company’s diverse offerings include a variety of dermal fillers, such as SkinPlus – Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses. Additionally, Bio Plus manufactures critical medical products: InterBlock, an absorbable anti-adhesion barrier; Synofil, utilized for synovial fluid replacement; and Blad-Care, a treatment for temporary alleviation of cystitis discomfort. Its mesotherapy portfolio features Kiara Reju for skin revitalization, Slim Slimmer for lipolysis, LumiDew for skin brightening, and JuveniHill for addressing wrinkles. The firm also supplies hair and scalp wellness products under the BelloHa and BellaChe names. Rounding out its extensive catalog are La Bella brand cosmetics, which include heparinoid essence, EGF balls, and specialized skin care gels.
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||